CARTALAX 20 MG

Dragon Pharma Cartalax 20 mg – Synthetic Tripeptide for Cartilage and Joint Research

Dragon Pharma Cartalax 20 mg is a synthetic short tripeptide with the amino acid sequence Ala-Glu-Asp (AED). Classified as a peptide bioregulator, this compound has been studied preclinically for its potential to support cartilage, joint health, and connective tissue maintenance by influencing gene expression in chondrocytes and other joint-related cells.

Each vial contains 20 mg of lyophilized Cartalax in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Cartalax represents a targeted research tool for investigating the molecular mechanisms underlying cartilage maintenance, chondrocyte function, and the biological processes involved in joint health. For related research compounds, explore our peptides category and specifically BPC 157 for complementary tissue repair research applications.

What Makes Cartalax Valuable in Research?

Cartalax belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The AED sequence has been studied for its ability to influence cellular processes relevant to cartilage and joint biology, including the regulation of gene expression in chondrocytes and the modulation of connective tissue metabolism. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of cartilage maintenance and joint function.

Researchers value Cartalax for its targeted approach to studying cartilage and connective tissue biology. Its ability to influence chondrocyte gene expression provides insights into the mechanisms that govern cartilage health and age-related changes in joint tissues. For investigators exploring other aspects of connective tissue research, TB 500 offers complementary research avenues in tissue repair and regeneration.

Current scientific literature on peptide bioregulators can be accessed through the PubMed database, where researchers can review peer-reviewed studies on related compounds and experimental applications.

Key Research Applications for Dragon Pharma Cartalax

• ✔ Investigation of chondrocyte gene expression and function
• ✔ Evaluation of cartilage maintenance and metabolism
• ✔ Research on connective tissue regulation and repair
• ✔ Studies of joint health and age-related changes
• ✔ Preclinical models of cartilage biology and joint function

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 20 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, Cartalax is typically administered via subcutaneous injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.

• ✔ Commonly used in cartilage and joint studies
• ✔ Often combined with histological and molecular analysis
• ✔ Used to investigate chondrocyte gene expression
• ✔ Research models include cartilage maintenance and joint health paradigms

Factors to Consider in Research Protocols

• Short-chain peptide with specific bioregulatory properties
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across subjects
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma Cartalax 20 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions